Caris Life Sciences, Inc. (CAI) |
| 26.4 0.8 (3.13%) 01-13 16:00 |
| Open: | 25.66 |
| High: | 27.17 |
| Low: | 24.6901 |
| Volume: | 3,127,767 |
| Market Cap: | 7,449(M) |
| PE Ratio: | -7.5 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 29.32 |
| Resistance 1: | 27.55 |
| Pivot price: | 27.63 |
| Support 1: | 24.69 |
| Support 2: | 20.54 |
| 52w High: | 42.5 |
| 52w Low: | 22.86 |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
| EPS | -3.520 |
| Book Value | 1.700 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.384 |
| Profit Margin (%) | -28.81 |
| Operating Margin (%) | 15.05 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Tue, 13 Jan 2026
A Look At Caris Life Sciences (CAI) Valuation After The Everlywell Caris Detect Partnership And 2025 Outlook - simplywall.st
Tue, 13 Jan 2026
Caris Life Sciences stock holds steady as Canaccord maintains $30 target - Investing.com Nigeria
Mon, 12 Jan 2026
Caris Life Sciences (NASDAQ:CAI) Trading Down 9.8% - Here's What Happened - MarketBeat
Mon, 12 Jan 2026
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal - TechStock²
Mon, 12 Jan 2026
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results - PR Newswire
Mon, 12 Jan 2026
Caris and Everlywell team on blood test to catch cancers sooner - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |